Skip to main content
News Archive

Why Roche’s $1.9 Billion Deal to Buy Flatiron Health Matters – Fortune

By February 19, 2018May 22nd, 2025No Comments

roche-flatiron-logo

The big headline out of the health care M&A world today is Swiss pharmaceutical giant Roche’s $1.9 billion acquisition of Flatiron Health, the Alphabet-backed, cancer-focused digital health analytics upstart that’s attempting to use real world patient information and big data to spur better oncology R&D.

{iframe}http://fortune.com/2018/02/16/roche-flatiron-health-deal-why-it-matters/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.